Sandbox Reserved 1847
From Proteopedia
| Line 5: | Line 5: | ||
These mini proteins target the interaction between ACE2 and COVID-19 spike protein <ref name="Longxing">PMID:32907861</ref>. The mini binders are small proteins carefully designed to bind to the COVID-19 spike protein with a greater affinity than ACE2 <ref name="Longxing">PMID:32907861</ref>. These mini binders were able to reduce the viral burden of SARS-CoV-2 in mice <ref name="Case">PMID:34192518</ref>. These proteins were de novo (from scratch) designs to mimic the ACE2 helix, but have a lower dissociation constant, yielding a greater affinity for the spike protein <ref name="Longxing">PMID:32907861</ref>. <scene name='10/1075249/Binding_region/1'>Binding Region between spike protein and ACE2</scene> can give a better explanation as to how these proteins were designed. | These mini proteins target the interaction between ACE2 and COVID-19 spike protein <ref name="Longxing">PMID:32907861</ref>. The mini binders are small proteins carefully designed to bind to the COVID-19 spike protein with a greater affinity than ACE2 <ref name="Longxing">PMID:32907861</ref>. These mini binders were able to reduce the viral burden of SARS-CoV-2 in mice <ref name="Case">PMID:34192518</ref>. These proteins were de novo (from scratch) designs to mimic the ACE2 helix, but have a lower dissociation constant, yielding a greater affinity for the spike protein <ref name="Longxing">PMID:32907861</ref>. <scene name='10/1075249/Binding_region/1'>Binding Region between spike protein and ACE2</scene> can give a better explanation as to how these proteins were designed. | ||
===COVID-19 Disease Pathway=== | ===COVID-19 Disease Pathway=== | ||
| - | Understanding the pathway of the COVID-19 virus is essential to understanding the mechanism in which the virus’ surface proteins attach to the mini binders. The COVID-19 virus has spike proteins on its surface that bind to the host cell receptor known as ACE2 <ref name="Sang">PMID:36499120</ref. When the spike protein binds to a receptor, ACE2 for example, TM protease serine 2 promotes viral entry by activating the spike protein <ref name="Huang">PMID:32747721</ref>. The activated spike protein is able to cleave itself into S1 and S2 subunits, | + | Understanding the pathway of the COVID-19 virus is essential to understanding the mechanism in which the virus’ surface proteins attach to the mini binders. The COVID-19 virus has spike proteins on its surface that bind to the host cell receptor known as ACE2 <ref name="Sang">PMID:36499120</ref. When the spike protein binds to a receptor, ACE2 for example, TM protease serine 2 promotes viral entry by activating the spike protein <ref name="Huang">PMID:32747721</ref>. The activated spike protein is able to cleave itself into S1 and S2 subunits <ref name="Huang">PMID:32747721</ref>. The S2 subunit is in charge of viral entry and does this through conformational changes <ref name="Huang">PMID:32747721</ref>. The S2 subunit will insert it's FP domain into the host cell's membrane, and this will trigger an interaction with the HR2 domain and HR1 trimer to form the 6-helical bundle to bring the viral envelope and cell membrane in close enough distance for viral fusion and ultimately viral entry <ref name="Huang">PMID:32747721</ref>. Once the virus is within the host cell, it is able to translate viral proteins, eliciting an immune response and spreading the viral particles throughout the body <ref name="Huang">PMID:32747721</ref>. |
===COVID-19 Viral Infection Interruption=== | ===COVID-19 Viral Infection Interruption=== | ||
| - | The primary goal of the mini binders is to prevent the spike proteins from binding to ACE2, and when the mini binders are bound to the spike protein, the virus is unable to anchor itself to the host protein <ref name="Longxing">PMID:32907861</ref>. Because the mini binders have a greater binding affinity than ACE2 for the spike protein, they are able to effectively prevent the entry of the virus and ultimately prevent an immune response <ref name="Longxing">PMID:32907861</ref>. | + | The primary goal of the mini binders is to prevent the spike proteins from binding to ACE2, and when the mini binders are bound to the spike protein, the virus is unable to anchor itself to the host protein <ref name="Longxing">PMID:32907861</ref>. Because the mini binders have a greater binding affinity than ACE2 for the spike protein, they are able to effectively prevent the entry of the virus and ultimately prevent an immune response <ref name="Longxing">PMID:32907861</ref>. Targeting this specific interaction between the COVID-19 spike protein has proven effective and is hopeful target for future therapeutics to treat the virus <ref name="Huang">PMID:32747721</ref>. |
Revision as of 11:07, 10 April 2025
| This Sandbox is Reserved from March 18 through September 1, 2025 for use in the course CH462 Biochemistry II taught by R. Jeremy Johnson and Mark Macbeth at the Butler University, Indianapolis, USA. This reservation includes Sandbox Reserved 1828 through Sandbox Reserved 1846. |
To get started:
More help: Help:Editing |
Contents |
Structure
Introduction
What are Minibinders?
These mini proteins target the interaction between ACE2 and COVID-19 spike protein [1]. The mini binders are small proteins carefully designed to bind to the COVID-19 spike protein with a greater affinity than ACE2 [1]. These mini binders were able to reduce the viral burden of SARS-CoV-2 in mice [2]. These proteins were de novo (from scratch) designs to mimic the ACE2 helix, but have a lower dissociation constant, yielding a greater affinity for the spike protein [1]. can give a better explanation as to how these proteins were designed.
COVID-19 Disease Pathway
Understanding the pathway of the COVID-19 virus is essential to understanding the mechanism in which the virus’ surface proteins attach to the mini binders. The COVID-19 virus has spike proteins on its surface that bind to the host cell receptor known as ACE2 [3]. The activated spike protein is able to cleave itself into S1 and S2 subunits [4]. The S2 subunit is in charge of viral entry and does this through conformational changes [4]. The S2 subunit will insert it's FP domain into the host cell's membrane, and this will trigger an interaction with the HR2 domain and HR1 trimer to form the 6-helical bundle to bring the viral envelope and cell membrane in close enough distance for viral fusion and ultimately viral entry [4]. Once the virus is within the host cell, it is able to translate viral proteins, eliciting an immune response and spreading the viral particles throughout the body [4].
COVID-19 Viral Infection Interruption
The primary goal of the mini binders is to prevent the spike proteins from binding to ACE2, and when the mini binders are bound to the spike protein, the virus is unable to anchor itself to the host protein [1]. Because the mini binders have a greater binding affinity than ACE2 for the spike protein, they are able to effectively prevent the entry of the virus and ultimately prevent an immune response [1]. Targeting this specific interaction between the COVID-19 spike protein has proven effective and is hopeful target for future therapeutics to treat the virus [4].
Design
These mini binders, LCB1 and AHB2, were designed from “scratch” (de novo) with the intention to mimic the binding of ACE2 to spike protein (insert citation). Using Rotamer Interaction Field (RIF) docking, the proteins were able to make the most efficient bonding using the ACE2 spike protein binding interface (insert citation). Using Site Saturation Mutagenesis (SSM), every residue in the minibinder’s helix scaffold will be substituted with each of the 20 amino acids, one at a time (insert citation). Forming SSM libraries, each of the libraries converged on a small number of closely related sequences, and from these libraries, the design was selected for LCB1 and AHB2 to find the sequence that yields a protein with a high affinity for the spike proteins receptor binding domain (insert).
| |||||||||||
|

